Inovio Pharmaceuticals, Inc. (INO)
NASDAQ: INO · Real-Time Price · USD
1.760
-0.010 (-0.56%)
Apr 15, 2025, 4:00 PM EDT - Market closed
Inovio Pharmaceuticals Stock Forecast
INO's stock price has decreased by -84.04% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Inovio Pharmaceuticals stock have an average target of 12.2, with a low estimate of 3.00 and a high estimate of 20. The average target predicts an increase of 593.18% from the current stock price of 1.76.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Inovio Pharmaceuticals stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 4 | 4 | 4 | 4 | 3 | 3 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Maintains $6 → $5 | Hold | Maintains | $6 → $5 | +184.09% | Mar 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $3 | Hold | Reiterates | $3 | +70.45% | Mar 19, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $18 | Buy | Reiterates | $18 | +922.73% | Mar 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $5 → $3 | Hold | Maintains | $5 → $3 | +70.45% | Jan 13, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $18 | Buy | Reiterates | $18 | +922.73% | Jan 10, 2025 |
Financial Forecast
Revenue This Year
n/a
from 217.76K
Revenue Next Year
12.46M
EPS This Year
-2.63
from -3.95
EPS Next Year
-2.26
from -2.63
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 17.3M | 61.6M | ||
| Avg | n/a | 12.5M | 49.2M | ||
| Low | n/a | 9.7M | 38.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 394.7% | ||
| Avg | - | - | 295.2% | ||
| Low | - | - | 205.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.13 | -0.63 | -0.28 | ||
| Avg | -2.63 | -2.26 | -1.41 | ||
| Low | -4.36 | -3.34 | -2.46 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.